Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)
Key Information
Due Date: May 7, 2025
Agency: U.S. Department of Health and Human Services (HHS)
Source: Federal
Funding Category:
Health & Human Services
Funding Amount: $581,371
Funding Type: Grant
Match Required: No
Contact Info:
OERWebmaster03@od.nih.gov
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Overview
The primary aim of this Funding Opportunity Announcement (FOA) is to support efforts in identifying and initiating the biological, analytical, and clinical assessment of prospective biomarkers for neurological and neuromuscular conditions. Through this initiative, the goal is to generate potential biomarkers or biomarker signatures that are equipped for comprehensive analytical and clinical verification studies. This grant is open to clinical trials, but they are not mandatory, as indicated by the "R61/R33 Clinical Trial Optional" title.
Key Dates
Open Date: February 23, 2022
Application Due Date: May 7, 2025
Estimated Award Date: Not Specified
Additional Details
Eligible Activities
- Research and Development
Eligible Applicants
- State governments
- County governments
- City, village or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Private institutions of higher education
- Small businesses